Associations of A-FABP with Anthropometric and Metabolic Indices and Inflammatory Cytokines in Obese Patients with Newly Diagnosed Type 2 Diabetes

Table 3

Comparisons of blood biomarkers of study subjects.

Group	FBG; (mmol/L)	2hPG; (mmol/L)	HbA1C (%)	FINS; (mu/L)	2hINS; (mu/L)	C-P; (ng/mL)	2hC-P; (ng/mL)	HOMA-IR
Normal control	4.71 ± 1.2	5.72 ± 1.8	4.7 ± 0.4	13.7 ± 3.6	43.2 ± 7.63	1.46 ± 0.78	4.32 ± 1.30	2.91 ± 1.10
Simple obesity	4.96 ± 1.06	5.96 ± 1.23	5.1 ± 0.3	17.2 ± 1.7^☆	40.1 ± 3.72	1.56 ± 0.62	4.30 ± 0.98	4.70 ± 1.24^☆
Type 2 diabetes
Nonobese	9.25 ± 3.12^☆☆○○	12.56 ± 1.03^☆☆○○	8.7 ± 1.2^☆☆○○	23.6 ± 4.7^☆☆	52.7 ± 4.6^☆☆○○	3.03 ± 0.32^☆○	7.98 ± 0.72^☆☆○○	8.47 ± 3.7^☆☆○○
Obese	9.65 ± 2.16^☆☆○○	13.76 ± 2.53^☆☆○○	8.9 ± 0.9^☆☆○○	25.2 ± 8.7^☆☆	49.3 ± 5.3^☆☆○○	3.06 ± 0.43^☆○	8.76 ± 0.69^☆☆○○	11.3 ± 2.6^☆☆○○∆

FBG: fasting plasma glucose; 2hPG: 2 h postchallenge plasma glucose; HbA1C: glycated hemoglobin A1C; FINS: fasting insulin; 2hINS: 2 h postprandial insulin; C-P: C-peptide; 2hC-P: 2 h postprandial C-peptide; HOMA-IR: Homeostasis Model Assessment Index of insulin resistance. Data are mean ± SD or median. ^☆ < 0.05, ^☆☆ < 0.01 versus normal control; ^○ < 0.05, ^○○ < 0.01 versus simple obese group; ^∆ < 0.05 versus nonobese diabetic group.